Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BGMS. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BGMS is a Sell candidate.
BGMS stock price ended at $0.88 on 星期五, after dropping 11.11%
On the latest trading day May 08, 2026, the stock price of BGMS fell by 11.11%, dropping from $0.93 to $0.88. During the session, the stock saw a volatility of 8.05%, with prices oscillating between a daily low of $0.87 and a high of $0.94. On the latest trading day, the trading volume for BGMS rose by 20.7K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 30.0K shares were traded, with a market value of approximately $4.8M.